← back to search

Mark R. Denison

Bipar · US
Area of research
Infectious Diseases · Animal Science and Zoology
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, Animal Virus Infections Studies, Viral gastroenteritis research and epidemiology, and COVID-19 Clinical Research Studies.
h-index
64
citations
29,626
works
203
NIH funding
primary concept
Medicine
email

Recent publications

Loss of nsp14-exonuclease activity impairs the replication, proofreading, fitness, and pathogenesis of SARS-CoV-2.
2026cited by 0position: contributordoi
Mechanism and spectrum of inhibition of viral polymerases by 2'-deoxy-2'-β-fluoro-4'-azidocytidine or azvudine.
2025cited by 0position: contributordoi
The Coronavirus helicase in replication.
2024cited by 14position: contributordoi
Positive‐strand RNA viruses—a Keystone Symposia report
Annals of the New York Academy of Sciences 2023cited by 1position: middledoi
The Antiviral Mechanism of Action of Molnupiravir in Humans with COVID-19
2023cited by 1position: contributordoi
Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms.
2022cited by 194position: contributordoi
Neutralizing COVID-19 Convalescent Plasma in Adults Hospitalized With COVID-19
CHEST Journal 2022cited by 30position: middledoi
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.
2021cited by 630position: contributordoi
The coronavirus proofreading exoribonuclease mediates extensive viral recombination.
2021cited by 226position: contributordoi
Stabilized coronavirus spike stem elicits a broadly protective antibody
Cell Reports 2021cited by 104position: contributordoi
Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit
The Journal of Infectious Diseases 2021cited by 41position: middledoi
Reovirus RNA recombination is sequence directed and generates internally deleted defective genome segments during passage.
2021cited by 14position: contributordoi
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
New England Journal of Medicine 2020cited by 3,477position: middledoi
An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.
2020cited by 2,600position: contributordoi
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
Nature Communications 2020cited by 1,809position: middledoi
SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
Nature 2020cited by 1,639position: middledoi
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
New England Journal of Medicine 2020cited by 1,620position: middledoi
SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.
2020cited by 1,340position: contributordoi
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.
2020cited by 1,212position: contributordoi
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
Science Translational Medicine 2020cited by 1,158position: middledoi
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV.
2020cited by 1,073position: contributordoi
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.
2020cited by 882position: contributordoi
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
New England Journal of Medicine 2020cited by 827position: middledoi
Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice
Cell Reports 2020cited by 538position: middledoi
Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice.
2020cited by 445position: contributordoi
Multicenter Initial Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2
Journal of the Pediatric Infectious Diseases Society 2020cited by 187position: middledoi
Multicenter Interim Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2
Journal of the Pediatric Infectious Diseases Society 2020cited by 112position: middledoi
Multicenter Initial Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2.
2020cited by 91position: contributordoi
Reovirus RNA recombination is sequence directed and generates internally deleted defective genome segments during passage
2020cited by 0position: contributordoi
Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase
Antiviral Research 2019cited by 531position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 12 papers (2020–2026)Ralph S. Baric · University of North Carolina at Chapel Hill7 papers (2017–2026)Timothy P. Sheahan · Rockefeller University5 papers (2020–2026)Lingshu Wang · Hebei University of Economics and Business5 papers (2019–2021)Timothy P. Sheahan · University of North Carolina at Chapel Hill5 papers (2017–2020)Amy Sims · Georgia State University5 papers (2017–2020)Joy Y. Feng · Gilead Sciences (United States)4 papers (2017–2020)Tomáš Cihlář · Cambridge Health Alliance4 papers (2017–2020)Nicole A. Doria‐Rose · National Institutes of Health3 papers (2020–2021) · 3 papers (2020–2022) · 3 papers (2020–2021)Lisa A. Jackson · Kaiser Permanente Washington Health Research Institute3 papers (2020–2021) · 3 papers (2020–2021) · 3 papers (2020–2021)Inci Yildirim · Universidade Federal do Rio de Janeiro3 papers (2020–2021)Adrian B. McDermott · University of Bamako3 papers (2020–2021)Jason McLellan · Bridge University3 papers (2019–2021)Robert Jordan · University of Tennessee at Knoxville3 papers (2017–2020)Barney S. Graham · National Institute of Allergy and Infectious Diseases3 papers (2020–2021)Rachel L. Graham · University of North Carolina at Chapel Hill3 papers (2017–2019)